Inhibition of Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocyte (CTL) activity by soluble HLA class I in vitro

Clinical and Experimental Immunology

Volumn 119, Issue 1, 2000, Pages 107-114

  Gansuvd, B ^a,b   Hagihara, M ^a,c   Munkhbat, B ^b,c   Kanai, N ^a   Morita, N ^a   Munkhtuvshin, N ^b   Chargui, J ^a,d   Kato, S ^a,c   Hotta, T ^a   Tsuji, K ^a  

^a Dept of Haematol and Rheumatology ^*  (Japan)

^b Institute of Clinical Pathology   (Mongolia)

^c TOKAI UNIVERSITY   (Japan)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

Apoptosis; CTL; Epstein Barr virus; Soluble HLA class 1

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; HLA ANTIGEN CLASS 1;

APOPTOSIS; ARTICLE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; HLA SYSTEM; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS CELL TRANSFORMATION;

APOPTOSIS; B-LYMPHOCYTES; CELL LINE; CELL TRANSFORMATION, VIRAL; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HLA-B7 ANTIGEN; HUMANS; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033956201     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01092.x     Document Type: Article

References (29)

1. 1 Charlton RK, Zmijewski CM. Soluble HL-A7 antigen: localization in the β-lypoprotein fraction of human serum. Science 1970; 170:636-7.
2. 2 Van Rood JJ, Van Leeuwen A, Van Santen MCT. Anti HL-A2 inhibitor in normal human serum. Nature 1970; 226:366-7.
3. 3 Brieva JA, Villar LM, Leoro G, Alvarez-Cermeno JC, Roldan E, Gonzalez-Porque P. Soluble HLA class I antigen secretion by normal lymphocytes: relationship with cell activation and effect of interferon-gamma. Clin Exp Immunol 1990; 82:390-5.
4. 4 Puppo F, Brenci S, Ghio M et al. Serum HLA class I antigen levels in allogeneic bone marrow transplantation: a possible marker of acute GVHD. Bone Marrow Transplant 1996; 17:753-8.
5. 5 Liem LM, Koelman CA, Doxiadis IIN, Van Houwelingen JC, Goulmy E, Claas FHJ. Elevated serum HLA class I levels coincide with acute and chronic graft-versus-host-disease. Bone Barrow Transplant 1997; 20:227-34.
6. 6 Shimura T, Hagihara M, Yamamoto K, Takebe K, Munkhbat B, Tsuji K. Quantification of soluble forms of HLA in kidney transplantation. Transplant Proc 1994; 26:1891.
7. 7 Alvarez-Cermeno JC, Casado C, Villar LM et al. Soluble class I antigens (sHLA) in CSF and serum of patients with HIV infection. Acta Neurol Scand 1990; 82:14-6.
8. 8 Adarnashvili IM, McDonald JC, Fraser PA, Milford EL, Pressly TA, Gelder FB. Soluble class I HLA antigens in patients with rheumatoid arthritis and their families. J Rheumatal 1995; 22:1025-31.
9. 9 Nocito M, Montalban C, Gonzalez-Porque P, Villar LM. Increased soluble serum HLA class I antigens in patients with lymphoma. Hum Immunol 1997; 58:106-11.
10. 10 Zavazava N, Kronke M. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nature Med 1996; 2:1005-10.
11. 11 Hausmann R, Zavazava N, Steinmann J, Muller-Ruchholtz W. Interaction of papain-digested HLA class I molecules with human alloreactive cytotoxic T lymphocytes (CTL). Clin Exp Immunol 1993; 91:183-8.
12. 12 Dal Porto J, Johansen TE, Catipovic B et al. A soluble divalent class I MHC molecule inhibits alloreactive T cells at nanomolar concentrations. Proc Natl Acad Sci USA 1993; 90:6671-5.
13. 13 Tomkinson BE, Maziarz R, Sullivan JL. Characterization of the T cell-mediated cellular cytotoxicity during acute infectious mononucleosis. J Immunol 1989; 143:660-70.
14. 14 Sing AP, Ambinder RS, Hong DJ, Jenscn M, Batten W, Petersdorf E, Greenberg PD. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease. Blood 1997; 89:1978-86.
15. 15 Lucas KG, Small TN, Heller G, Dupont B, O'Reilly RJ. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996; 87:2594-603.
16. 16 Rhodes G, Carson DA, Valbracht J, Houghten R, Vaughan JH. Human immune responses to synthetic peptides from the Epstein-Barr nuclear antigen. J Immunol 1985; 134:211-6.
17. 17 Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, Sculley TB, Kieff E, Moss DJ. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 1992; 176:169-76.
18. + virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1. Virology 1996; 219:489-92.
19. 19 Zavazava N, Muller-Ruchholtz W. Quantitative and biochemical characterization of soluble HLA class I antigens shed by cultured human cells. Hum Immunol 1994; 40:174-8.
20. 20 Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4 and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992; 71:1065-8.
21. 21 Schneck J, Lee Maloy W, Coligan JE, Margulies DH. Inhibition of an allospecific T cell hybridoma by soluble class 1 proteins and peptides: estimation of the affinity of a T cell receptor for MHC. Cell 1989; 56:47-55.
22. 22 Spencer SC, Farbe JW. Bulk publication of a naturally occurring soluble form of RT1-A class 1 major histocompatibility complex antigens from DA rat liver, and studies of specific immunosuppression. Transplantation 1987; 44:141-8.
23. 23 Carl Grumet F, Kreshnaswamy S, See-Tho K, Filvaroff E, Hiraki DD. Soluble form of an HLA-B7 class I antigen specifically suppresses humoral alloimmunization. Hum Immunol 1994; 40:228-34.
24. 24 Hiraki DD, See-Tho K, Filvaroff E, Krishnaswamy S, De Bello W, Taidi-Laskowski B, Carl Grumet F. Bioengineered soluble HLA-B7 genesis, characterization and occurrence of dimerization. Hum Immunol 1994; 40:235-46.
25. 25 Zavazava N, Hausmann R, Muller-Ruchholtz W. Inhibition of anti-HLA-B7 alloreactive CTL by affinity-purified soluble HLA. Transplantation 1991; 51:838-42.
26. 26 Casanova JL, Cerottini JC, Matthes M et al. H-2-restricted cytolytic T lymphocytes specific for HLA display T cell receptors of limited diversity. J Exp Med 1992; 176:439-47.
27. 27 Springer TA, Strominger JL, Mann DL. Partial purification of detergent-soluble HLA antigen and its cleavage by papain. Proc Natl Acad Sci USA 1974; 71:1539-43.
28. 28 Dobbe LME, Stam NJ, Neefkes JJ, Giphart MJ. Biochemical complexity of serum HLA class 1 molecules. Immunogenetics 1988; 27:203-10.
29. 29 Krangel MS. Secretion of HLA-A and -B antigens via an alternative RNA splicing pathway. J Exp Med 1986; 163:1173-90.